Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at greater risk.
Lin Xie, MS, MA
Advertisement
Articles by Lin Xie, MS, MA
Advertisement
Latest Updated Articles
Journey to Anticoagulant Access Following Payer Rejection of ApixabanPublished: November 7th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
